Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: Nature. 2014 May 21;510(7504):283–287. doi: 10.1038/nature13320

Extended Data Figure 8. SMYD3 knockout augments the effects of the MEK1/2 inhibitor Trametinib (GSK1120212) in vivo.

Extended Data Figure 8

a, Schematic of the caerulein pancreatitis-induced tumorigenesis protocol. Mice were treated with a normal dose of Trametinib (1mg/kg IP daily) or a low dose (0.1mg/kg IP daily) or vehicle control. b, Immunoblot analysis with indicated antibodies of two independent pancreas biopsies per treatment group. c, Quantification of MUC5-positive lesions in caerulein-treated pancreata from Kras and Kras;Smyd3 mutant mice treated with Trametinib or vehicle control (n=5, each treatment). *: p-value<0.05; ***: p-value<0.001 (two-tailed unpaired Student's t-test). Data are represented as mean +/− SEM. d, Representative macroscopic pictures of pancreata from each treatment group. Scale bar, 1 cm. e, Representative serial HE staining and IHC for pERK1/2, a marker of Ras activity, and MUC5, a marker of PanIN lesions. All scale bars, 50 μm.